Exicure (NASDAQ:XCUR) vs. ProQR Therapeutics (NASDAQ:PRQR) Financial Analysis

ProQR Therapeutics (NASDAQ:PRQR) and Exicure (NASDAQ:XCUR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Profitability

This table compares ProQR Therapeutics and Exicure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
Exicure	N/A	-237.91%	-61.98%

Volatility and Risk

ProQR Therapeutics has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Comparatively, Exicure has a beta of 3.63, indicating that its share price is 263% more volatile than the S&P 500.

Insider and Institutional Ownership

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Comparatively, 52.8% of Exicure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for ProQR Therapeutics and Exicure, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1	1	6	0	2.62
Exicure	1	0	0	0	1.00

ProQR Therapeutics presently has a consensus price target of $7.50, indicating a potential upside of 309.84%. Given ProQR Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe ProQR Therapeutics is more favorable than Exicure.

Valuation and Earnings

This table compares ProQR Therapeutics and Exicure”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99 million	10.72	-$47.73 million	($0.46)	-3.98
Exicure	$500,000.00	16.11	-$4.95 million	($1.32)	-0.93

Exicure has lower revenue, but higher earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

About Exicure

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.